ECKERT & ZIEGLER BG 
By Regulated information
Year Results 2010
A second year with a Net Profit
March 30, 2011
Seneffe - Belgium, March 30, 2011, IBt Bebig (Reuters: IBTH.BR - Bloomberg: IBTB BB) has announced today its consolidated results for the year ending December 31, 2010.
A summary report including the milestones of the year 2010 and a selection of consolidated key figures for the 12 months ending December 31, 2010 can be downloaded at:
http://www.ibt-bebig.eu/en/investor_relations/financial_reports/interim_results.html:
http://www.ibt-bebig.eu/en/investor_relations/financial_reports/interim_results.html
Sales for the year 2010 reached EUR 32.4 million, compared to EUR 30.7 million in 2009, showing an increase of 5.5%. As last year, the main components were income generated by the sales of permanent brachytherapy I-125 radiotherapeutic implants as well as income from temporary brachytherapy equipment, i.e. HDR equipment using Co-60 (Cobalt 60) and Ir-192 (Iridium 192) sources (also called "afterloaders").
Operating result reached EUR 6.0 million for the whole year 2010 compared to EUR 5.3 million in 2009, showing an increase of 11.3%. Whereas this number shows further improvement in operational performance, earnings before interest and taxes (EBIT) were hit by a financial charge of EUR 1.4 million in 2010 due to the write-off of the USD 2 million investment in Core Oncology. As a result, EBIT reached EUR 4.2 million for the whole year 2010 compared to EUR 5.3 million in 2009.
Net profit reached EUR 4.3 million in 2010, compared to the net profit of EUR 4.4 million in 2009.
Total Equity of the group stood at EUR 37.6 million on December 31, 2010, versus EUR 33.4 million in 2009.
IBt Bebig continued to maintain a solid financial situation, with cash amounting to EUR 5.2 million at the end of December 2010, versus EUR 9.6 million a year earlier. Cash decreased due to cash received in 2009 as prepayment in relationship to the Russian venture and used in 2010.
The Annual Report 2010 will be available on our website by April 30, 2011
Shareholders Calendar
Trading Update 1Q-2011: Tuesday May 3, 2011
Annual General Meeting: Monday June 6, 2011 (10:30 am)
Half-Year Results 2011: Tuesday August 2, 2011
Trading Update 3Q-2011: Wednesday November 2, 2011
Annual Results 2011 Friday March 30, 2012
The above results and trading updates will be published before market opens on the respective dates.
IBt Bebig
. Contributing to saving lives!
IBt Bebig is a European-based group active in the medical device sector of the health care industry.
Its core business is the treatment of cancer by brachytherapy, a special form of radiotherapy. IBt Bebig is a leader in brachytherapy in Europe and is headquartered in Belgium. It has a production facility in Germany and subsidiaries throughout Europe, as well as in India. IBt Bebig has also established a worldwide network of distributors and agents to support its product line.
The company's products and equipment are intended for use by oncologists, radiologists, urologists, and medical physicists.
IBt Bebig employs more than 150 people. It has been listed on the Euronext stock exchange since April 1997 (Reuters: IBTH.BR - Bloomberg: IBTB BB).
Contact
Paul-Emmanuel Goethals
Vice President Business Development & Capital Markets, IBt Bebig
Special Counsel to the CEO, Eckert & Ziegler AG
Tel.: +32 64 520 808
Email: ir@ibt-bebig.eu:
mailto:ir@ibt-bebig.eu
Internet: www.ibt-bebig.eu:
http://www.ibt-bebig.eu/
The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.
Source: IBt Bebig via Thomson Reuters ONE
